Home | Welcome to Contract Pharma   
Last Updated Wednesday, April 16 2014
Print

Isis Earns GSK Milestone



Published December 2, 2013
Related Searches: Phase II
Isis Pharmaceuticals, Inc. has earned a $2 million milestone payment from GlaxoSmithKline for the advancement of an ongoing Phase II/III study of ISIS-TTR in patients with familial amyloid polyneuropathy (FAP), a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues.
 
The Phase II/III study is a randomized, double-blind, placebo-controlled, study will support an application for marketing approval of ISIS-TTR in patients with FAP. The study will measure the effects of ISIS-TTR on neurological dysfunction and on quality-of-life. 
 
To date, Isis has earned more than $20 million in upfront and milestone payments for advancing ISIS-TTR. Also, if GSK elects to exercise its option to exclusively license the ISIS-TTR program, Isis is eligible to receive a license fee, regulatory and sales milestones, and royalties on sales.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On